Live Breaking News & Updates on Sustained Pharmacokinetic Profile

Metacrine Reports Positive Results from Phase 1 Trial of MET642
MET642 Demonstrated Sustained Pharmacokinetic Profile and Robust FXR Target Engagement with Once-Daily Oral Dosing, without Pruritis or LDL-Cholesterol Increase
Doses Selected for Phase 2a Trial in Patients with NASH; On-Track to Initiate in 1H21
SAN DIEGO, Dec. 17, 2020 (GLOBE NEWSWIRE) Metacrine, Inc. (Nasdaq: MTCR), a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with liver and gastrointestinal diseases, today reported preliminary results from its Phase 1 trial of MET642, a farnesoid X receptor (FXR) agonist being developed for the treatment of non-alcoholic steatohepatitis (NASH) and inflammatory bowel disease. Findings show that treatment with MET642 was safe and generally well-tolerated and demonstrated a sustained pharmacokinetic (PK) profile and robust FXR target engagement after 14 days of daily oral dosing in healthy volunte ....

Stephena Harrison , Chelcie Lister , Hubertc Chen , Exchange Commission , Strategic Communications , Pinnacle Clinical Research , Metacrine Inc , Summit Clinical Research , Sustained Pharmacokinetic Profile , Once Daily Oral Dosing , Visiting Professor , Radcliffe Department , Medical Director , Summit Clinical , Target Engagement , Private Securities Litigation Reform Act , Quarterly Report , பரிமாற்றம் தரகு , மூலோபாய தகவல்தொடர்புகள் , உச்சம் மருத்துவ ஆராய்ச்சி , உச்சிமாநாடு மருத்துவ ஆராய்ச்சி , ஒரு முறை தினசரி வாய்வழி வீரியம் , வருகை ப்ரொஃபெஸர் , ராட்க்ளிஃப் துறை , மருத்துவ இயக்குனர் , உச்சிமாநாடு மருத்துவ ,